Children immunised

What we measure: The number of children immunised with the last recommended dose of a Gavi-supported vaccine delivered through routine systems.a People immunised through campaigns and supplementary immunisation activities are not included.

M1

Future deaths prevented

What we measure: The number of anticipated future deaths prevented as a result of vaccination with Gavi-funded vaccines in the countries we support.

M2

Under-five mortality rate

What we measure: The average probability of a child born in any of the Gavi- supported countries dying before they reach the age of five.

M3

Future disability-adjusted life years averted

What we measure: The number of anticipated future disability-adjusted life years (DALYs) averted as a result of vaccination with Gavi-supported vaccines. DALYs measure the number of healthy years lost due to disability or premature death.

M4

Vaccines sustained after Gavi support ends

What we measure: The percentage of countries that continue to deliver all recommended vaccines included in their routine programmes after they transition out of Gavi financing. This indicator covers all vaccines recommended by national authorities for routine immunisation, not only those supported by Gavi.

M5

Disease dashboard

Our goal is to reduce the overall disease burden in Gavi-supported countries. Therefore we also monitor the proportion of countries with low prevalence of three vaccine-preventable diseases – measles, rotavirus diarrhoea and hepatitis B – as part of a “disease dashboard”.

Measles

What we measure: The percentage of Gavi-supported countries reporting fewer than five measles cases per million people annually.

Rotavirus

What we measure: The median proportion of acute gastroenteritis hospitalisations in children under one year in Gavi-supported countries testing positive for rotavirus.

Hepatitis B

What we measure: The percentage of Gavi-supported countries with low prevalence of hepatitis in children under five.


a To ensure that we do not double-count children who receive more than one vaccine, we only take into account the Gavi-supported vaccine with the highest coverage level in each country.

 


Some figures from previous years have been updated due to revisions of historical data.

Our 2016-2020 strategy

Last updated: 4 Dec 2019

Subscribe to our newsletter